Spirooxindoles: Promising scaffolds for anticancer agents

European Journal of Medicinal Chemistry

Volumn 97, Issue 1, 2015, Pages 673-698

  Yu, Bin ^a   Yu, De Quan ^a   Liu, Hong Min ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Cancer therapy; Oxindole; Spirooxindoles; Synthesis

Indexed keywords

ALKALOID; ANTINEOPLASTIC AGENT; MI 888; OXINDOLE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; INDOLE DERIVATIVE; SPIRO COMPOUND;

ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; CANCER THERAPY; CYCLOADDITION; DRUG ISOLATION; DRUG SYNTHESIS; HUMAN; ISOMERIZATION; NONHUMAN; REVIEW; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; INDOLES; SPIRO COMPOUNDS;

EID: 84903246603     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.06.056     Document Type: Review

References (84)

1. P. Irigaray, D. Belpomme, Basic properties and molecular mechanisms of exogenous chemical carcinogens, Carcinogenesis 31 (2010) 135-148.
2. For more information about worldwide cancer incidence and mortality in 2012 (data released in February 2014), please visit Cancer Research UK website (http://www.cancerresearchuk.org).
3. A. Gupta, B. Sathish Kumar, A.S. Negi, Current status on development of steroids as anticancer agents, J. Steroid Biochem. Mol. Biol. 137 (2013) 242-270.
4. R. Rios, Enantioselective methodologies for the synthesis of spiro compounds, Chem. Soc. Rev. 41 (2012) 1060-1074.
5. N.R. Ball-Jones, J.J. Badillo, A.K. Franz, Strategies for the enantioselective synthesis of spirooxindoles, Org. Biomol. Chem. 10 (2012) 5165-5181.
6. C.V. Galliford, K.A. Scheidt, Pyrrolidinyl-spirooxindole natural products as inspirations for the development of potential therapeutic agents, Angew. Chem. Int. Ed. 46 (2007) 8748-8758.
7. L. Hong, R. Wang, Recent advances in asymmetric organocatalytic construction of 3,3′-spirocyclic oxindoles, Adv. Synth. Catal. 355 (2013) 1023-1052.
8. M. Rottmann, C. McNamara, B.K.S. Yeung, M.C.S. Lee, B. Zou, B. Russell, P. Seitz, D.M. Plouffe, N.V. Dharia, J. Tan, S.B. Cohen, K.R. Spencer, G.E. González-Páez, S.B. Lakshminarayana, A. Goh, R. Suwanarusk, T. Jegla, E.K. Schmitt, H.-P. Beck, R. Brun, F. Nosten, L. Renia, V. Dartois, T.H. Keller, D.A. Fidock, E.A. Winzeler, T.T. Diagana, Spiroindolones, a potent compound class for the treatment of malaria, Science 329 (2010) 1175-1180.
9. Y. Zhao, S. Yu, W. Sun, L. Liu, J. Lu, D. McEachern, S. Shargary, D. Bernard, X. Li, T. Zhao, P. Zou, D. Sun, S. Wang, A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice, J. Med. Chem. 56 (2013) 5553-5561.
10. M.A. Borad, M.N. Bhoi, N.P. Prajapati, H.D. Patel, Review of synthesis of spiro heterocyclic compounds from isatin, Synth. Commun. 44 (2013) 897-922.
11. A.K. Franz, N.V. Hanhan, N.R. Ball-Jones, Asymmetric catalysis for the synthesis of spirocyclic compounds, ACS Catal. 3 (2013) 540-553.
12. M.A. Borad, M.N. Bhoi, N.P. Prajapati, H.D. Patel, Review of synthesis of multispiro heterocyclic compounds from isatin, Synth. Commun. 44 (2013) 1043-1057.
13. Y. Liu, H. Wang, J. Wan, Recent advances in diversity oriented synthesis through isatin-based multicomponent reactions, Asian J. Org. Chem. 2 (2013) 374-386.
14. G.S. Singh, Z.Y. Desta, Isatins as privileged molecules in design and synthesis of spiro-fused cyclic frameworks, Chem. Rev. 112 (2012) 6104-6155.
15. M. Xia, R.-Z. Ma, Recent progress on routes to spirooxindole systems derived from isatin, J. Heterocycl. Chem. 51 (2013) 539-554.
16. C.-B. Cui, H. Kakeya, H. Osada, Novel mammalian cell cycle inhibitors, Spirotryprostatins A and B, produced by Aspergillus fumigatus, which inhibit mammalian cell cycle at G2/M phase, Tetrahedron 52 (1996) 12651-12666.
17. S. Edmondson, S.J. Danishefsky, L. Sepp-Lorenzino, N. Rosen, Total synthesis of Spirotryprostatin A, leading to the discovery of some biologically promising analogues, J. Am. Chem. Soc. 121 (1999) 2147-2155.
18. N. Bacher, M. Tiefenthaler, S. Sturm, H. Stuppner, M.J. Ausserlechner, R. Kofler, G. Konwalinka, Oxindole alkaloids from Uncaria tomentosa induce apoptosis in proliferating, G0/G1-arrested and Bcl-2-expressing acute lymphoblastic leukaemia cells, Br. J. Haematol. 132 (2006) 615-622.
19. E. García Prado, M.D. García Gimenez, R. De la Puerta Vázquez, J.L. Espartero Sánchez, M.T. Sáenz Rodríguez, Antiproliferative effects of mitraphylline, a pentacyclic oxindole alkaloid of Uncaria tomentosa on human glioma and neuroblastoma cell lines, Phytomedicine 14 (2007) 280-284.
20. D. Garcia Gimenez, E. Garcia Prado, T. Saenz Rodriguez, A. Fernandez Arche, De la Puerta, Cytotoxic effect of the pentacyclic oxindole alkaloid mitraphylline isolated from Uncaria tomentosa bark on human ewing's sarcoma and breast cancer cell lines, Planta Med. 76 (2010) 133-136.
21. S. Kaiser, F. Dietrich, P.E. d. Resende, S.G. Verza, R.C. Moraes, F.B. Morrone, A.M.O. Batastini, G.G. Ortega, Cat's claw oxindole alkaloid isomerization induced by cell incubation and cytotoxic activity against T24 and RT4 human bladder cancer cell lines, Planta Med. 79 (2013) 1413-1420.
22. K. Wang, X.-Y. Zhou, Y.-Y. Wang, M.-M. Li, Y.-S. Li, L.-Y. Peng, X. Cheng, Y. Li, Y.-P. Wang, Q.-S. Zhao, Macrophyllionium and macrophyllines A and B, oxindole alkaloids from uncaria macrophylla, J. Nat. Prod. 74 (2010) 12-15.
23. P.H. Kussie, S. Gorina, V. Marechal, B. Elenbaas, J. Moreau, A.J. Levine, N.P. Pavletich, Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain, Science 274 (1996) 948-953.
24. M. Aeluri, S. Chamakuri, B. Dasari, S.K.R. Guduru, R. Jimmidi, S. Jogula, P. Arya, Small molecule modulators of proteineprotein interactions: selected case studies, Chem. Rev. 114 (2014) 4640-4694.
25. K. Ding, Y. Lu, Z. Nikolovska-Coleska, S. Qiu, Y. Ding, W. Gao, J. Stuckey, K. Krajewski, P.P. Roller, Y. Tomita, D.A. Parrish, J.R. Deschamps, S. Wang, Structure-based design of potent non-peptide MDM2 inhibitors, J. Am. Chem. Soc. 127 (2005) 10130-10131.
26. S.H. Sun, M. Zheng, K. Ding, S. Wang, Y. Sun, A small molecule that disrupts MDM2-p53 binding activates p53, induces apoptosis, and sensitizes lung cancer cells to chemotherapy, Cancer Biol. Ther. 7 (2008) 845-852.
27. K. Ding, Y. Lu, Z. Nikolovska-Coleska, G. Wang, S. Qiu, S. Shangary, W. Gao, D. Qin, J. Stuckey, K. Krajewski, P.P. Roller, S. Wang, Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction, J. Med. Chem. 49 (2006) 3432-3435.
28. R. Fan, T.S. Kumaravel, F. Jalali, P. Marrano, J.A. Squire, R.G. Bristow, Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression, Cancer Res. 64 (2004) 8526-8533.
29. J.A. Canner, M. Sobo, S. Ball, B. Hutzen, S. DeAngelis, W. Willis, A.W. Studebaker, K. Ding, S. Wang, D. Yang, J. Lin, MI-63: a novel smallmolecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53, Br. J. Cancer 101 (2009) 774-781.
30. L.T. Vassilev, B.T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, E.A. Liu, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2, Science 303 (2004) 844-848.
31. X. Wu, J.H. Bayle, D. Olson, A.J. Levine, The p53-MDM2 autoregulatory feedback loop, Genes. Dev. 7 (1993) 1126-1132.
32. S. Shangary, K. Ding, S. Qiu, Z. Nikolovska-Coleska, J.A. Bauer, M. Liu, G. Wang, Y. Lu, D. McEachern, D. Bernard, C.R. Bradford, T.E. Carey, S. Wang, Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer, Mol. Cancer Ther. 7 (2008) 1533-1542.
33. C. Saddler, P. Ouillette, L. Kujawski, S. Shangary, M. Talpaz, M. Kaminski, H. Erba, K. Shedden, S. Wang, S.N. Malek, Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia, Blood 111 (2008) 1584-1593.
34. S. Shangary, D. Qin, D. McEachern, M. Liu, R.S. Miller, S. Qiu, Z. Nikolovska-Coleska, K. Ding, G. Wang, J. Chen, D. Bernard, J. Zhang, Y. Lu, Q. Gu, R.B. Shah, K.J. Pienta, X. Ling, S. Kang, M. Guo, Y. Sun, D. Yang, S. Wang, Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition, Proc. Natl. Acad. Sci. 105 (2008) 3933-3938.
35. A. Sosin, A. Burger, A. Siddiqi, J. Abrams, R. Mohammad, A. Al-Katib, HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas, J. Hematol. Oncol. 5 (2012) 1-18.
36. R. Mohammad, J. Wu, A. Azmi, A. Aboukameel, A. Sosin, S. Wu, D. Yang, S. Wang, A. Al-Katib, An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals, Mol. Cancer 8 (2009) 1-14.
37. S. Yu, D. Qin, S. Shangary, J. Chen, G. Wang, K. Ding, D. McEachern, S. Qiu, Z. Nikolovska-Coleska, R. Miller, S. Kang, D. Yang, S. Wang, Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction, J. Med. Chem. 52 (2009) 7970-7973.
38. H. Caner, E. Groner, L. Levy, I. Agranat, Trends in the development of chiral drugs, Drug Discov. Today 9 (2004) 105-110.
39. Y. Zhao, L. Liu, W. Sun, J. Lu, D. McEachern, X. Li, S. Yu, D. Bernard, P. Ochsenbein, V. Ferey, J.-C. Carry, J.R. Deschamps, D. Sun, S. Wang, Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors, J. Am. Chem. Soc. 135 (2013) 7223-7234.
40. Q. Ding, Z. Zhang, J.-J. Liu, N. Jiang, J. Zhang, T.M. Ross, X.-J. Chu, D. Bartkovitz, F. Podlaski, C. Janson, C. Tovar, Z.M. Filipovic, B. Higgins, K. Glenn, K. Packman, L.T. Vassilev, B. Graves, Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development, J. Med. Chem. 56 (2013) 5979-5983.
41. Z. Zhang, X.-J. Chu, J.-J. Liu, Q. Ding, J. Zhang, D. Bartkovitz, N. Jiang, P. Karnachi, S.-S. So, C. Tovar, Z.M. Filipovic, B. Higgins, K. Glenn, K. Packman, L. Vassilev, B. Graves, Discovery of potent and orally active p53-MDM2 inhibitors RO5353 and RO2468 for potential clinical development, ACS Med. Chem. Lett. 5 (2013) 124-127.
42. L.M. Lima, E.J. Barreiro, Bioisosterism: a useful strategy for molecular modification and drug design, Curr. Med. Chem. 12 (2005) 23-49.
43. G.A. Patani, E.J. LaVoie, Bioisosterism: a rational approach in drug design, Chem. Rev. 96 (1996) 3147-3176.
44. J. Gu, Y. Gui, L. Chen, G. Yuan, H.-Z. Lu, X. Xu, Use of natural products as chemical library for drug discovery and network pharmacology, PLoS One 8 (2013) e62839.
45. A.P. Antonchick, C. Gerding-Reimers, M. Catarinella, M. Schürmann, H. Preut, S. Ziegler, D. Rauh, H. Waldmann, Highly enantioselective synthesis and cellular evaluation of spirooxindoles inspired by natural products, Nat. Chem. 2 (2010) 735-740.
46. Y. Tian, S. Nam, L. Liu, F. Yakushijin, K. Yakushijin, R. Buettner, W. Liang, F. Yang, Y. Ma, D. Horne, R. Jove, Spirooxindole derivative SOID-8 induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells, PLoS One 7 (2012) e49306.
47. A.S. Girgis, Regioselective synthesis of dispiro[1H-indene-2,3′-pyrrolidine-2′,3″-[3H]indole]-1,2″(1″H)-diones of potential anti-tumor properties, Eur. J. Med. Chem. 44 (2009) 91-100.
48. A.S. Girgis, J. Stawinski, N.S.M. Ismail, H. Farag, Synthesis and QSAR study of novel cytotoxic spiro[3H-indole-3,2′(1′H)-pyrrolo[3,4-c]pyrrole]-2,3′,5′(1H,2′a-H,4′H)-triones, Eur. J. Med. Chem. 47 (2012) 312-322.
49. R.F. George, N.S.M. Ismail, J. Stawinski, A.S. Girgis, Design, synthesis and QSAR studies of dispiroindole derivatives as new antiproliferative agents, Eur. J. Med. Chem. 68 (2013) 339-351.
50. Y. Arun, K. Saranraj, C. Balachandran, P.T. Perumal, Novel spirooxindole-pyrrolidine compounds: synthesis, anticancer and molecular docking studies, Eur. J. Med. Chem. 74 (2014) 50-64.
51. A. Kumar, G. Gupta, S. Srivastava, A.K. Bishnoi, R. Saxena, R. Kant, R.S. Khanna, P.R. Maulik, A. Dwivedi, Novel diastereoselective synthesis of spiropyrrolidine-oxindole derivatives as anti-breast cancer agents, RSC Adv. 3 (2013) 4731-4735.
52. J.-M. Yang, Y. Hu, Q. Li, F. Yu, J. Cao, D. Fang, Z.-B. Huang, D.-Q. Shi, Efficient and regioselective synthesis of novel functionalized dispiropyrrolidines and their cytotoxic activities, ACS Comb. Sci. 16 (2014) 139-145.
53. A. Hazra, Y.P. Bharitkar, D. Chakraborty, S.K. Mondal, N. Singal, S. Mondal, A. Maity, R. Paira, S. Banerjee, N.B. Mondal, Regio- and stereoselective synthesis of a library of bioactive dispiro-oxindolo/acenaphthoquino andrographolides via 1,3-dipolar cycloaddition reaction under microwave irradiation, ACS Comb. Sci. 15 (2012) 41-48.
54. S.K. Dey, D. Bose, A. Hazra, S. Naskar, A. Nandy, R.N. Munda, S. Das, N. Chatterjee, N.B. Mondal, S. Banerjee, K.D. Saha, Cytotoxic activity and apoptosis-inducing potential of di-spiropyrrolidino and di-spiropyrrolizidino oxindole andrographolide derivatives, PLoS One 8 (2013) e58055.
55. B. Yu, X.-J. Shi, J.-l. Ren, X.-N. Sun, P.-P. Qi, Y. Fang, X.-W. Ye, M.-M. Wang, J.-W. Wang, E. Zhang, D.-Q. Yu, H.-M. Liu, Efficient construction of novel D-ring modified steroidal dienamides and their cytotoxic activities, Eur. J. Med. Chem. 66 (2013) 171-179.
56. B. Yu, X.-J. Shi, Y.-F. Zheng, Y. Fang, E. Zhang, D.-Q. Yu, H.-M. Liu, A novel [1,2,4] triazolo [1,5-a] pyrimidine-based phenyl-linked steroid dimer: synthesis and its cytotoxic activity, Eur. J. Med. Chem. 69 (2013) 323-330.
57. L.-H. Huang, Y.-F. Zheng, Y.-Z. Lu, C.-J. Song, Y.-G. Wang, B. Yu, H.-M. Liu, Synthesis and biological evaluation of novel steroidal[17,16-d][1,2,4]triazolo [1,5-a]pyrimidines, Steroids 77 (2012) 710-715.
58. B. Yu, X.-N. Sun, X.-J. Shi, P.-P. Qi, Y. Fang, E. Zhang, D.-Q. Yu, H.-M. Liu, Stereoselective synthesis of novel antiproliferative steroidal (E, E) dienamides through a cascade aldol/cyclization process, Steroids 78 (2013) 1134-1140.
59. B. Yu, E. Zhang, X.-N. Sun, J.-L. Ren, Y. Fang, B.-L. Zhang, D.-Q. Yu, H.-M. Liu, Facile synthesis of novel D-ring modified steroidal dienamides via rearrangement of 2H-pyrans, Steroids 78 (2013) 494-499.
60. B.-L. Zhang, E. Zhang, L.-P. Pang, L.-X. Song, Y.-F. Li, B. Yu, H.-M. Liu, Design and synthesis of novel D-ring fused steroidal heterocycles, Steroids 78 (2013) 1200-1208.
61. B. Yu, X.-J. Shi, P.-P. Qi, D.-Q. Yu, H.-M. Liu, Design, synthesis and biological evaluation of novel steroidal spiro-oxindoles as potent antiproliferative agents, J. Steroid Biochem. Mol. Biol. 141 (2014) 121-134.
62. M. Kidwai, A. Jain, V. Nemaysh, R. Kumar, P. Luthra, Efficient entry to diversely functionalized spirooxindoles from isatin and their biological activity, Med. Chem. Res. 22 (2013) 2717-2723.
63. 2 catalyzed three component reaction: efficient synthesis of spiro[indoline-3,4′-pyrano[3,2-b]pyran derivatives and their anticancer potency towards A549 human lung cancer cell lines, Bioorg. Med. Chem. Lett. 23 (2013) 2708-2713.
64. C. Han, T. Zhang, A. Zhang, D. Wang, W. Shi, J. Tao, Efficient catalyst-free onepot three-component synthesis of novel spirooxindole derivatives, and their cytotoxic activities, Synthesis 46 (2014) 1389-1398.
65. S.S. Maigali, M. El-Hussieny, F.M. Soliman, Chemistry of phosphorus ylides. Part 37. The reaction of phosphonium ylides with indoles and naphthofurans. Synthesis of phosphanylidenes, pyrans, cyclobutenes, and pyridazine as antitumor agents, J. Heterocycl. Chem. (2014), http://dx.doi.org/10.1002/jhet.1911.
66. X. Jiang, Y. Sun, J. Yao, Y. Cao, M. Kai, N. He, X. Zhang, Y. Wang, R. Wang, Core scaffold-inspired concise synthesis of chiral spirooxindole-pyranopyrimidines with broad-spectrum anticancer potency, Adv. Synth. Catal. 354 (2012) 917-925.
67. E.C.B. da Costa, R. Amorim, F.C. da Silva, D.R. Rocha, M.P. Papa, L.B. de Arruda, R. Mohana-Borges, V.F. Ferreira, A. Tanuri, L.J. da Costa, S.B. Ferreira, Synthetic 1,4-pyran naphthoquinones are potent inhibitors of dengue virus replication, PLoS One 8 (2013) e82504.
68. F.-F. Pan, W. Yu, Z.-H. Qi, C. Qiao, X.-W. Wang, Efficient construction of chiral spiro[benzo[g]chromene-oxindole] derivatives via organocatalytic asymmetric cascade cyclization, Synthesis 46 (2014) 1143-1156.
69. H.-L. Cui, F. Tanaka, Novel spirooxindole derivative and process for producing the same. WO 2014/058035A1; April, 17, 2014.
70. M. Pilátová, M. Šarišský, P. Kutschy, A. Miroššay, R. Mezencev, Z. Čurillová, M. Suchý, K. Monde, L. Mirossay, J. Mojžiš, Cruciferous phytoalexins: antiproliferative effects in T-Jurkat leukemic cells, Leuk. Res. 29 (2005) 415-421.
71. K. Monde, T. Taniguchi, N. Miura, P. Kutschy, Z. Čurillová, M. Pilátová, J. Mojžiš, Chiral cruciferous phytoalexins: preparation, absolute configuration, and biological activity, Bioorg. Med. Chem. 13 (2005) 5206-5212.
72. A. Bertamino, C. Aquino, M. Sala, N.d. Simone, C.A. Mattia, L. Erra, S. Musella, P. Iannelli, A. Carotenuto, P. Grieco, E. Novellino, P. Campiglia, I. Gomez-Monterrey, Design and synthesis of spirotryprostatin-inspired diketopiperazine systems from prolyl spirooxoindolethiazolidine derivatives, Bioorg. Med. Chem. 18 (2010) 4328-4337.
73. I. Gomez-Monterrey, A. Bertamino, A. Porta, A. Carotenuto, S. Musella, C. Aquino, I. Granata, M. Sala, D. Brancaccio, D. Picone, C. Ercole, P. Stiuso, P. Campiglia, P. Grieco, P. Ianelli, B. Maresca, E. Novellino, Identification of the spiro(oxindole-3,3′-thiazolidine)-based derivatives as potential p53 activity modulators, J. Med. Chem. 53 (2010) 8319-8329.
74. W. Tan, X.-T. Zhu, S. Zhang, G.-J. Xing, R.-Y. Zhu, F. Shi, Diversity-oriented synthesis of spiro-oxindole-based 2,5-dihydropyrroles via three-component cycloadditions and evaluation on their cytotoxicity, RSC Adv. 3 (2013) 10875-10886.
75. G.M. Popowicz, A. Dömling, T.A. Holak, The structure-based design of MDM2/Mdmxep53 inhibitors gets serious, Angew. Chem. Int. Ed. 50 (2011) 2680-2688.
76. C.J.A. Ribeiro, J.D. Amaral, C.M.P. Rodrigues, R. Moreira, M.M.M. Santos, Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents, Bioorg. Med. Chem. 22 (2014) 577-584.
77. S.R. Yong, A.T. Ung, S.G. Pyne, B.W. Skelton, A.H. White, Synthesis of novel 30-spirocyclic-oxindole derivatives and assessment of their cytostatic activities, Tetrahedron 63 (2007) 5579-5586.
78. Â. Monteiro, L.M. Gonçalves, M.M.M. Santos, Synthesis of novel spiropyrazoline oxindoles and evaluation of cytotoxicity in cancer cell lines, Eur. J. Med. Chem. 79 (2014) 266-272.
79. W. Rzeski, J. Matysiak, M. Kandefer-Szerszé, Anticancer, neuroprotective activities and computational studies of 2-amino-1,3,4-thiadiazole based compound, Bioorg. Med. Chem. 15 (2007) 3201-3207.
80. H.-Q. Liu, D.-C. Wang, F. Wu, W. Tang, P.-K. Ouyang, Synthesis and biological evaluation of 5′-phenyl-3′H-spiro-[indoline-3,2′-[1,3,4]oxadiazol]-2-one analogs, Chin. Chem. Lett. 24 (2013) 929-933.
81. W. Bains, R. Tacke, Silicon chemistry as a novel source of chemical diversity in drug design, Curr. Opin. Drug Discov. Dev. 6 (2003) 526-543.
82. A.K. Franz, P.D. Dreyfuss, S.L. Schreiber, Synthesis and cellular profiling of diverse organosilicon small molecules, J. Am. Chem. Soc. 129 (2007) 1020-1021.
83. L. Huang, X. Zhang, J. Li, K. Ding, X. Li, W. Zheng, B. Yin, Synthesis, skeletal rearrangement, and biological activities of spirooxindoles: exploration of a stepwise C-piancatelli rearrangement, Eur. J. Org. Chem. 2014 (2014) 338-349.
84. M. Kitajima, T. Nakamura, N. Kogure, M. Ogawa, Y. Mitsuno, K. Ono, S. Yano, N. Aimi, H. Takayama, Isolation of gelsedine-type indole alkaloids from gelsemium elegans and evaluation of the cytotoxic activity of gelsemium alkaloids for A431 epidermoid carcinoma cells, J. Nat. Prod. 69 (2006) 715-718.